Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)

NCT03664024 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Pemetrexed
DRUG: Carboplatin
DRUG: Cisplatin

Sponsor

Merck Sharp & Dohme LLC